2 weeks Ago By Defense World Staff
Sei Investments Co. increased its position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) by 55.
7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,082 shares of the company’s stock after purchasing an additional 24,723 shares during the period. Sei Investments Co.
owned 0.07% of Biohaven worth $2,580,000 at the end of the most recent reporting period. A number of other large investors also recently modified their holdings of BHVN.
Spire Wealth Management purchased a new position in shares of Biohaven in the fourth quarter valued at $56,000. Amalgamated Bank increased its holdings in shares of Biohaven by 21.9% in the 4th quarter.
Amalgamated Bank now owns 2,929 shares of the company’s stock worth $109,000 after buying an additional 527 shares during the last quarter. US Bancorp DE raised its position in shares of Biohaven by 36.7% during the 4th quarter.
US Bancorp DE now owns 2,971 shares of the company’s stock valued at $111,000 after buying an additional 798 shares in the last quarter. KBC Group NV lifted its holdings in shares of Biohaven by 50.1% in the 4th quarter.
KBC Group NV now owns 3,377 shares of the company’s stock valued at $126,000 after acquiring an additional 1,127 shares during the last quarter. Finally, Parallax Volatility Advisers L.P.
purchased a new position in Biohaven in the third quarter worth about $258,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.
Insider Transactions at BiohavenIn related news, Director John W. Childs acquired 32,700 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was bought at an average price of $30.
47 per share, for a total transaction of $996,369.00. Following the completion of the purchase, the director now directly owns 2,320,571 shares of the company’s stock, valued at approximately $70,707,798.
37. The trade was a 1.43 % increase in their position.
The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 16.00% of the company’s stock.
Biohaven Stock Down 9.8 %NYSE:BHVN opened at $18.54 on Friday.
Biohaven Ltd. has a 52 week low of $17.93 and a 52 week high of $55.
70. The stock’s fifty day moving average is $33.40 and its two-hundred day moving average is $40.
80. The company has a market capitalization of $1.89 billion, a P/E ratio of -1.
98 and a beta of 1.33. Biohaven (NYSE:BHVN – Get Free Report) last issued its quarterly earnings data on Monday, March 3rd.
The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.
29). Sell-side analysts anticipate that Biohaven Ltd. will post -8.
9 earnings per share for the current fiscal year. Analyst Ratings ChangesA number of brokerages recently issued reports on BHVN. Cantor Fitzgerald restated an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th.
Deutsche Bank Aktiengesellschaft set a $60.00 target price on shares of Biohaven and gave the stock a “buy” rating in a report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $54.
00 price target on shares of Biohaven in a report on Tuesday, March 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of Biohaven in a research note on Tuesday, March 4th.
Finally, JPMorgan Chase & Co. dropped their target price on Biohaven from $72.00 to $68.
00 and set an “overweight” rating for the company in a research report on Wednesday, March 5th. Fourteen investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $62.
77.View Our Latest Report on BiohavenBiohaven Company Profile (Free Report)Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide.
The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.Featured ArticlesFive stocks we like better than BiohavenWhat is Short Interest? How to Use ItArcher Aviation’s Africa Deal Could Boost ACHR StockInsider Trades May Not Tell You What You ThinkAre Short Sellers Wrong About These 3 Semiconductor Stocks?What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole StoryBoeing Gets $50B in March Orders—Is BA Stock a Buy Now?Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Ltd.
(NYSE:BHVN – Free Report)..
